Hepatotoxicity due to isoniazide in a patient with Crohn’s disease: Case report and literature review [Hepatotoxicidad por isoniazida en un paciente con enfermedad de Crohn. Reporte de caso y revisión de la literatura]
Reyes M G.A.,Clinica Universitaria Colombia |
Carvajal P G.D.,Residente de Gastroenterologia y Endoscopia Digestiva |
Tapias M M.L.,Medico Internista y Hepatologa adscrita a Colsanitas |
Sabbagh S L.C.,Fundacion Universitaria Sanitas
Revista Colombiana de Gastroenterologia | Year: 2016
Isoniazid is used for treatment or prophylaxis of tuberculosis but may be associated with adverse hepatic reactions. Clinically manifest hepatitis occurs in 0.5%-1% of patients who receive isoniazid as monotherapy. This article describes the case of a patient with Crohn’s disease who experienced severe hepatotoxicity due to isoniazid. It also reviews the literature. © 2016 Asociaciones Colombianas de Gastroenterología, Endoscopia digestiva, Coloproctología y Hepatología.
PubMed | International Psoriasis Council, University of Chile, Clinica Dermacross, Dermatology Ambulatory and 7 more.
Type: Review | Journal: The Journal of dermatology | Year: 2016
Latin American countries view biosimilar agents as an effective approach to curtail health-care expenditures while maintaining the safety and efficacy profile of their branded innovator comparators. To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Council convened dermatology experts from Argentina, Brazil, Chile, Colombia and Mexico in October 2015 to review the definition, approval, marketing and future of biosimilars in each country and develop a consensus statement. The regulatory framework for marketing approval of biosimilars in Latin America is currently a mosaic of disparate, country-specific, regulatory review processes, rules and standards, with considerable heterogeneity in clarity and specificity. Regulations in Argentina, Brazil, Chile and Mexico have undergone multiple refinements whereas Colombia is finalizing draft guidelines. Verification of the similarity in quality, safety and efficacy of biosimilars to the innovator biologic remains a key challenge for policy makers and regulatory authorities. Other key regulatory challenges include: naming of agents and traceability, pharmacovigilance, extrapolation of indications, and interchangeability and substitution. An urgent need exists for more Latin American countries to establish national psoriasis registries and to integrate their common components into a multinational psoriasis network, thereby enhancing their interpretative power and impact. A Latin American psoriasis network similar to PSONET in Europe would assist health-care providers, pharmaceutical companies, regulators and patients to fully comprehend specific products being prescribed and dispensed and to identify potential regional trends or differences in safety or outcomes.
Loss of follow-up and associated factors in patients enrolled in the HIV/aids program of the hospital universitario san ignacio, Colombia, 2012-2013 [Pérdida de seguimiento y factores asociados en pacientes inscritos en el programa de HIV/sida del hospital universitario san ignacio, Colombia, 2012-2013]
Tamara-Ramirez J.R.,Pontifical Xavierian University |
Alvarez C.A.,Clinica Universitaria Colombia |
Rodriguez J.,Pontifical Xavierian University
Biomedica | Year: 2016
Introduction: Regular long-term clinical follow-up is an important component of HIV care. Objective: To describe the reasons for follow-up loss among patients enrolled in the HIV/AIDS program of a university hospital. Materials and methods: A nested case-control study was carried out on a retrospective cohort between January 1st, 2012 and July 31st, 2013. Results: A group of 45 patients was selected; the incidence density rate of patients lost to follow-up was 17.7 per 100 patient/years. The following variables were significantly linked to follow-up loss in the bivariate analysis: Unemployment (p=0.000); alcohol consumption (p=0.004); number of years of evolution of the disease (p=0.032); gender (p=0.027), and mean age of 34 years (p=0.000). When logistic regression was adjusted for the probability of follow-up loss the significant variables were: Mean age of 34 years (p=0.019, 95% CI: 0.871-0.976); female (p=0.017, 95% CI: 1.903-31.83); alcohol consumption (p=0.028, 95% CI: 0.040-0.830), and unemployment (p=0.001, 95% CI: 4.696-464.692). Conclusions: HIV/AIDS programs need to establish follow-up systems and means to trace any losses in order to establish strategies to improve patient retention and, thus, their long-term quality of life.
Aponte J.A.P.,Fundacion Universitaria Sanitas |
Martin D.M.A.,Clinica Universitaria Colombia
Revista Colombiana de Gastroenterologia | Year: 2012
Spontaneous intramural hematoma of the esophagus constitutes a rare spectrum of esophageal injuries. Chest pain, diffi culty swallowing and hematemesis are the most common symptoms. They resolve spontaneously in most cases. Awareness of this condition is a vital guide for following up these cases and for avoiding inappropriate treatment and unnecessary surgical intervention. We report the case of a patient who presented with chest pain and hematemesis.
Clinical issues, serological issues and treatment of chronic hepatitis C at two medical centers in Bogotá, Colombia [Hepatitis C crónica: Aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia]
Prieto Ortiz J.E.,Clinica Universitaria Colombia |
Sanchez Pardo S.,Fundacion Universitaria Sanitas |
Rojas Diaz L.,Clinica Universitaria Colombia |
Huertas Pacheco S.,Clinica Universitaria Colombia
Revista Colombiana de Gastroenterologia | Year: 2014
Introduction: Hepatitis C affects about 170 million people worldwide. The World Health Organization (WHO) has estimated global prevalence at 2%. Overall, about 40% of patients respond to dual therapy treatment for genotype. In Colombia data available for confirm a similar pattern and for describing the clinical characteristics of patients with this infection are scarce. Methods: Medical records of patients in the Hepatology outpatient service at the Clínica Universitaria Colombia who had been diagnosed with chronic hepatitis C by one of the authors between January 1, 2010 and May 30, 2013 were retrospectively reviewed for clinical characteristics, serological characteristics and treatment responses. Results: The medical records of 163 patients were evaluated: 62% were female, 38% were male, and their mean age was 58.2 years. The main risk factor for acquiring hepatitis C was a history of transfusions before 1992. This factor was present in 62% of the patients. The decision to start treatment was made for 77 patients (47.2%), but 86 patients (52.8%) did not start treatment. Reasons included advanced age and advanced cirrhosis which together accounted for more than 50% of these patients. Other reasons for not starting treatment were minimal disease (4.7%), minimal sign of disease plus advanced age (10.5%), spontaneous healing (14%), low probability of response (3.3%) and others (14%). Of the 62 patients for whom information about previous or recent treatments was available, 30.6% had sustained virological responses (SVR), 29.0% were classified as relapsers, 8.1% as partial responders, 19.4% had no response, and 12.9% discontinued treatment because of intolerance. Conclusions: The most frequent antecedent of HCV in the group of patients studied a history of transfusions associated with gynecological surgery before 1992. About half of the patients were diagnosed late. Hepatitis was more likely to have been treated in these patients than in patients in other studies, but the SVR rate was similar to those found in other series. This study opens doors to the realization of other studies to more broadly define the prevalence, risk factors and treatment response variables of this entity in our country. © 2014 Asociaciones Colombianas de Gastroenterología, Endoscopia digestiva, Coloproctología y Hepatología
Acosta Izquierdo L.,Residencia de Radiologia e Imagenes Diagnosticas |
Mora Salazar J.A.,Clinica Universitaria Colombia |
Tramontini C.,Clinica Universitaria Colombia
Revista Chilena de Radiologia | Year: 2016
Post-transplantation lymphoproliferative disorder is a low incidence complication of transplant recipient patients. However, mortality is high if the diagnosis and management are not appropriate. For this reason the radiologist should be aware when dealing with images of these patients, particularly in the first year following the transplantation. In this article the case is presented of a woman who was recipient of a kidney, and developed post-transplantation lymphoproliferative disorder, affecting the central nervous system. © 2016 SOCHRADI.
Amaya-Guio J.,National University of Colombia |
Viveros-Carreno D.A.,National University of Colombia |
Sierra-Barrios E.M.,National University of Colombia |
Martinez-Velasquez M.Y.,Clinica Universitaria Colombia |
Grillo-Ardila C.F.,National University of Colombia
Cochrane Database of Systematic Reviews | Year: 2016
Background: Bacterial vaginosis (BV) is an infection that has a prevalence between 10% to 50% worlwide. BV results in an imbalance of the normal vaginal flora. Microorganisms associated with BV have been isolated from the normal flora of the male genital tract, and their presence could be related to the recurrence of BV after antibiotic treatment. Therefore, the treatment of sexual partners could decrease the recurrence of infection and possibly the burden of the disease. Objectives: To assess the effectiveness in women and the safety in men of concurrent antibiotic treatment for the sexual partners of women treated for BV. Search methods: We searched the Cochrane Sexually Transmitted Infections Group Specialized Register (23 July 2016), CENTRAL (1991 to 23 July 2016), MEDLINE (1946 to 23 July 2016), Embase (1974 to 23 July 2016), LILACS (1982 to 23 July 2016), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (23 July 2016), ClinicalTrials.gov (23 July 2016) and the Web of Science™ (2001 to 23 July 2016). We also handsearched conference proceedings, contacted trial authors and reviewed the reference lists of retrieved studies. Selection criteria: Randomized controlled trials (RCTs) that compared the concurrent use of any antibiotic treatment with placebo, no intervention or any other intervention by the sexual partners of women treated for BV. Data collection and analysis: Three review authors independently assessed trials for inclusion, extracted data and assessed the risk of bias in the included studies. We resolved any disagreements through consensus. We assessed the quality of the evidence using the GRADE approach. Main results: Seven RCTs (1026 participants) met our inclusion criteria, and pharmaceutical industry funded four of these trials. Five trials (854 patients) compared any antibiotic treatment of sexual partners with placebo. Based on high quality evidence, antibiotic treatment does not increase the rate of clinical or symptomatic improvement in women during the first week (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.96 to 1.03; 712 participants, four studies; RR 1.06, 95% CI 1.00 to 1.12; 577 patients, three studies, respectively), between the first and fourth week (RR 1.02, 95% CI 0.94 to 1.11; 590 participants, three studies; RR 0.93, 95% CI 0.84 to 1.03; 444 participants, two studies; respectively) or after the fourth week (RR 0.98, 95% CI 0.90 to 1.07; 572 participants, four studies; RR 1.03, 95% CI 0.90 to 1.17; 296 participants, two studies; respectively). Antibiotic treatment does not led to a lower recurrence during the first and fourth week (RR 1.28, 95% CI 0.68 to 2.43; 218 participants, one study; low quality evidence) or after the fourth week of treatment (RR 1.00, 95% CI 0.67 to 1.52; 372 participants, three studies; low quality evidence) in women, but increases the frequency of adverse events (most frequently gastrointestinal symptoms) reported by sexual partners (RR 2.55, 95% CI 1.55 to 4.18; 477 participants, three studies; low quality evidence).Two trials (172 participants) compared any antibiotic treatment for sexual partners with no intervention. When we compared it with no intervention, the effects of antibiotic treatment on recurrence rate after the fourth week (RR 1.71, 95% CI 0.65 to 4.55; 51 participants, one study), clinical improvement between the first and fourth week (RR 0.93, 95% CI 0.70 to 1.25; 152 participants, two studies) and symptomatic improvement after the fourth week (RR 0.66, 95% CI 0.39 to 1.11; 70 participants, one study) were imprecise and there were no differences between groups. We downgraded the quality of the evidence to low or very low. Authors' conclusions: High quality evidence shows that antibiotic treatment for sexual partners of women with BV, compared with placebo, does not increase the rate of clinical or symptomatic improvement during the first, between the first and fourth or after the fourth week into the women. Low quality evidence suggests that antibiotic treatment does not led to a lower recurrence rate during the first and fourth or after the fourth week of treatment into the women, but increases the frequency of adverse events reported by sexual partners. Finally, compared with no intervention, antibiotic treatment does not decrease the recurrence rate after the fourth week and does not increase the frequency of clinical or symptomatic improvement between the first and fourth or after the fourth week into the women, respectively. © 2016 The Cochrane Collaboration.
PubMed | El Rosario University and Clinica Universitaria Colombia
Type: Journal Article | Journal: Journal of clinical medicine research | Year: 2015
Idiopathic peripartum cardiomyopathy presenting with heart failure is a true diagnostic and treatment challenge. Goal oriented clinical management aims at the relapse of left ventricular systolic dysfunction. A 35-year-old patient on her 12th day post-delivery presents progressive signs of heart failure. Transthoracic echocardiography showed severe mitral insufficiency, mild left ventricular dysfunction, mild tricuspid insufficiency, severe pulmonary hypertension, and right atrial enlargement. With wet and cold heart failure signs, the patient was a candidate for inodilator cardiovascular support and volume depletion therapy. As the patient presented a persistent tachycardia at rest, levosimendan was chosen over dobutamine. Levosimendan was administered at a dose of 0.2 g/kg/min during a period of 24 hours. After inodilator therapy, the patients signs and symptoms of heart failure began to decrease, showing improvement of dyspnea, mitral murmur grade went from IV/IV to II/IV, filling pressures and systemic and pulmonary resistance indexes decreased, arterial blood gases improved, and an echocardiography performed 72 h later showed non-dilated cardiomyopathy, mild cardiac contractile dysfunction, mild mitral insufficiency, type I diastolic dysfunction and improvement of pulmonary hypertension. Cardiovascular function in peripartum cardiomyopathy tends to go back to normality in 23-41% of the cases, but in a large group of patients, severe ventricle dysfunction remains months after initial symptoms. This article describes the diagnostic process of a patient with peripartum cardiomyopathy and a successful reversion of a severe case of mitral insufficiency using levosimendan as a new therapeutic strategy in this clinical context.
Changing Sgarbossa criteria for the diagnosis of acute myocardial infarction in the presence of left bundle branch [Modificación de los criterios de Sgarbossa para el diagnóstico de infarto agudo de miocardio en presencia de bloqueo de rama izquierda]
Moreno-Ruiz N.L.,Clinica Universitaria Colombia
Revista Facultad de Medicina | Year: 2015
The left bundle branch block diagnosis difficult acute myocardial infarction. Sgarbossa criteria mentioned in the guidelines for the management of various scientific societies, are useful but well-recognized limitations. Recently posted a modification to these criteria can improve diagnostic performance and thus be part of a management algorithm of these patients, but so far research is needed to validate do this. © 2015, Universidad Nacional de Colombia. All rights reserved.
PubMed | Clinica Universitaria Colombia
Type: Case Reports | Journal: Biomedica : revista del Instituto Nacional de Salud | Year: 2014
Paracoccidioidomycosis is one of the most prevalent systemic fungal infections in Latin American countries. The incidence rate has been increasing and its detection has gotten increasingly common in travelers or immigrants from endemic areas. It is characterized by respiratory symptoms, lymphadenopathies and skin lesions, which gradually progress and subsequently lead to death in some untreated chronic disease cases.To describe the clinical approach and diagnosis of an exotic tropical pathology in an urban area.Case description and extended literature review. We made a case report of urban paracoccidioidomycosis in a young patient, with a clinical syndrome of fever for a month, widespread nodal involvement, cutaneous manifestations and weight loss. During the physical examination, hepatosplenomegaly and a febrile episode were evidenced, whose diagnosis was difficult. Management started with itraconazole and trimethoprim sulfamethoxazole, with subsequent cessation of spiking fevers and significant improvement of the skin lesions. We performed a comprehensive literature review, with search criteria performed in PubMed and adapted for different databases. The review was conducted based on the studies found in Medline, LILACS, SciELO and Cochrane Library, from 1966 up to this moment. Studies were selected by the authors based on their relevance and scientific contribution to the discussion of this case.There are few cases of paracoccidiomycosis in the pediatric population despite the endemicity of this entity in Latin America. An increasing population influx from endemic areas makes suspecting of this disease a must.